Global Neuralgia Partnering 2010-2017

Publisher Name :
Date: 01-Apr-2017
No. of pages: 150
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Provides understanding and access to the neuralgia partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Neuralgia Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

• Trends in partnering deals

• Top deals by value

• Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Global Neuralgia Partnering Terms and Agreements since 2010 report provides the reader with the following key benefits:

• In-depth understanding of deal trends since 2010

• Access to headline, upfront, milestone and royalty data

• Comprehensive access to multiple deals entered into by the world's biopharma companies since 2010

• Insight into key deal terms included in contracts, where disclosed

• Understand the key deal terms companies have agreed in deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Neuralgia Partnering 2010-2017

Table of Contents
Executive Summary

Chapter 1 - Therapy partnering trends in numbers
Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development

Chapter 2 - Most active dealmakers

Chapter 3 - Partnering deals directory
Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area

Chapter 4 - Partnering deals with a contract document

Chapter 5 - M&A in numbers
M&A in numbers - by year

Chapter 6 - M&A deals directory
M&A deals directory - by company A-Z
M&A deals directory - by deal value

Chapter 7 - Financing in numbers
Financing in numbers - by year
Financing in numbers - by financing type

Chapter 8 - Financing deals directory
Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering

List of Figures

Figure 1: Partnering frequency by year
Figure 2: Partnering most active
Figure 3: Partnering by industry sector
Figure 4: Partnering by deal type
Figure 5: Partnering by technology area
Figure 6: Partnering by stage of development
Figure 7: M&A frequency by year
Figure 8: Financing frequency by year
Figure 9: Financing by type
  • United States Gabapentin Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Gabapentin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Gabap......
  • Encephalomyelitis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 62
    Encephalomyelitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2017, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape. Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Amo......
  • Epilepsy - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 420
    Epilepsy - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H2 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and sho......
  • Nicotine Addiction - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 63
    Nicotine Addiction - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H2 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape. Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post......
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 163
    Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape. Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that includ......
  • Global Epilepsy Therapeutics Market Research Report 2017
    Published: 16-Aug-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Epilepsy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Epilepsy Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Global Gabapentin Sales Market Report 2017
    Published: 11-Aug-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Gabapentin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units) , revenue (Million USD) , market share and growth rate of Gabapentin for these regions, from 2012 to 2022 (forecast) , covering - United States - China - Europe - Japan - So......
  • Global Gabapentin Market Research Report 2017
    Published: 07-Aug-2017        Price: US 2900 Onwards        Pages: 106
    In this report, the global Gabapentin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Gabapentin in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan ......
  • Spasticity - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Spasticity -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Spasticity in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Spasticity. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Spasticity. The report contains the targeted patient populations and the forecast method......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs